| pubmed-article:20673586 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20673586 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20673586 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:20673586 | lifeskim:mentions | umls-concept:C0282625 | lld:lifeskim |
| pubmed-article:20673586 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:20673586 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20673586 | pubmed:dateCreated | 2010-12-20 | lld:pubmed |
| pubmed-article:20673586 | pubmed:abstractText | This report aims to more accurately define the frequency of the involvement of SRC Family Kinases (SFKs) in imatinib- and dasatinib-resistant CML patients. Clinical samples were analysed during in vivo treatment. We confirmed the high frequency of SFKs involvement in Tyrosine kinase inhibitor-resistant CML (52% of the cases) and even further in progressive disease and blast crises (60% of the cases). The SFKs deregulation is also observed in patients harboring BCR-ABL mutations. In T315I and F317L mutated patients, CML-resistance appears to be promoted by SFKs kinase protein reactivation once the BCR-ABL mutated clone has decreased on Omacetaxine. | lld:pubmed |
| pubmed-article:20673586 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20673586 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20673586 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20673586 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:20673586 | pubmed:issn | 1873-5835 | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:MichalletMaur... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:MagaudJean-Pi... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:Cony-MakhoulP... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:Maguer-SattaV... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:HayetteSandri... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:NicoliniFranc... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:ChabaneKaddou... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:MichallatEste... | lld:pubmed |
| pubmed-article:20673586 | pubmed:author | pubmed-author:SalesseStépha... | lld:pubmed |
| pubmed-article:20673586 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20673586 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20673586 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:20673586 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20673586 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20673586 | pubmed:pagination | 38-43 | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:meshHeading | pubmed-meshheading:20673586... | lld:pubmed |
| pubmed-article:20673586 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20673586 | pubmed:articleTitle | Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. | lld:pubmed |
| pubmed-article:20673586 | pubmed:affiliation | Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratory for Molecular Biology and UMR5239 CNRS, Pierre-Bénite, France. sandrine.hayette@chu-lyon.fr | lld:pubmed |
| pubmed-article:20673586 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20673586 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20673586 | lld:pubmed |
